e-learning
resources
Munich 2014
Monday, 08.09.2014
Biology and pathology of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis
A. J. Ruiz Reina, M. Gonzalez, E. Vazquez, R. I. Aguilar Perez Grovas, I. Vazquez Rico, T. Garcia Barrera, J. Gravalos Guzman, J. L. Sanchez Ramos, J. A. Maldonado Perez, J. L. Gomez Ariza, A. Pereira Vega (Huelva, Spain)
Source:
International Congress 2014 – Biology and pathology of thoracic tumours
Session:
Biology and pathology of thoracic tumours
Session type:
Thematic Poster Session
Number:
2694
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. J. Ruiz Reina, M. Gonzalez, E. Vazquez, R. I. Aguilar Perez Grovas, I. Vazquez Rico, T. Garcia Barrera, J. Gravalos Guzman, J. L. Sanchez Ramos, J. A. Maldonado Perez, J. L. Gomez Ariza, A. Pereira Vega (Huelva, Spain). Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis. Eur Respir J 2014; 44: Suppl. 58, 2694
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Metabolomic analysis of serum samples from patients with lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Methilation status in EBUS-NA samples of lung cancer
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Relationship between risk factors for lung cancer and tumor size
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Symptom-to-treatment intervals in lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Lung cancer in women: Is it different?
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
The value of miR221 and miR222 as a biomarker in non small cell lung cancer
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Potential genetic markers for the early diagnosis of peripheral and metastatic lung cancer
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level?
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Epigenetic alterations in the circulating DNA from blood of patients with COPD and lung cancer
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Weight loss cutoff level as a key variable related to death risk among advanced lung cancer patients
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Association between leptin and risk of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Evaluation of lung cancer patients with distant organ metastasis
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Functional impairment of NK cells in non-small-cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Polymorphism of
HLA-G
gene promotor in patients with non small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Comorbitities, responses and survival in pts with NSCLC
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Accelerated lung function decline increases the risk of lung cancer
Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer
Year: 2013
The research on early detection of lung cancer with exhaled volatile organic compounds
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Exhaled breath temperature in NSCLC: Could be a new non invasive marker?
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Radiation pneumonitis; early diagnosis and associated factors
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept